The successful clinical application of conventional CAR-αβ T cells has been largely confined to hematologic malignancies, whereas their efficacy against solid tumors and non-malignant chronic diseases remains severely limited by MHC restriction, T cell exhaustion, poor tissue infiltration, and an immunosuppressive microenvironment. The gene discussed is HLA-C; the disease is cancer.